CAS: 914361-45-8

Fosravuconazole L-lysine ethanolate, a prodrug for ravuconazole, treats onychomycosis in Japan.

Fosravuconazole L-lysine ethanolate

Fosravuconazole L-lysine ethanolate

Fosravuconazole L-lysine ethanolate is an antifungal prodrug, which is a derivative of the widely used antifungal agent ravuconazole. This compound is synthesized through chemical modification to enhance its bioavailability and aqueous solubility, addressing limitations found in its parent compound. Fosravuconazole is designed to undergo in vivo conversion to ravuconazole, its active form, by enzymatic processes within the body. Fosravuconazole L-lysine ethanolate exhibits potent antifungal activity through its mechanism of inhibiting the enzyme lanosterol 14α-demethylase (CYP51). This enzyme is crucial in the biosynthesis of ergosterol, an essential component of fungal cell membranes. Inhibition of this pathway results in impaired cell membrane formation and, ultimately, cell death. The primary use of Fosravuconazole L-lysine ethanolate is in the treatment of various systemic fungal infections, particularly those caused by Candida and Aspergillus species. It is researched for its use in both immunocompromised and non-immunocompromised patients, highlighting its potential in treating invasive mycoses with a favorable safety profile.